Therapeutics Prescribing Safety

Nausea and vomiting of pregnancy and hyperemesis gravidarum

Fejzo MS, Trovik J, Grooten IJ, Sridharan K, Roseboom TJ, Vikanes Å, Painter RC, Mullin PM

Published September 12, 2019 Nature reviews. Disease primers, 5(1), 62
DOI 10.1038/s41572-019-0110-3 PMID 31515515

RRM Academy Synopsis

Up to 70% of pregnant women have nausea and vomiting, review says

A 2019 review in Nature Reviews Disease Primers reports that pregnancy nausea and vomiting affects up to 70% of pregnant women. The severe form, hyperemesis, has been reported in 0.3-10.8% of pregnant women and can be associated with poor outcomes for mothers, fetuses and children.

Key Findings

  • As many as 70% of pregnant women are affected by nausea and vomiting of pregnancy.
  • Reported rates of hyperemesis gravidarum, usually seen as the severe form, range from 0.3-10.8% of pregnant women, and no consensus definition exists.
  • Diet and lifestyle changes can manage symptoms in the majority of affected women. More than one-third have symptoms that may call for fluids, vitamins or antiemetic medication.
  • Common variants in genes for the placental proteins GDF15 and IGFBP7 and the receptors GFRAL and PGR suggest that the placenta plays a part in the cause.

Interpretation

The source is the published abstract of a Nature Reviews Disease Primers review. The synopsis sums up the authors' overview and reflects only what the abstract states. The authors report that doxylamine/pyridoxine taken together is not teratogenic and may be effective for treatment. They write that studies are urgently needed to learn if ondansetron is safer and more effective than first-line antiemetics.

RRM Context

Restorative reproductive medicine looks for the biological basis of a condition. Genetic findings on placental proteins fit that approach, since they suggest the placenta plays a part in the cause of severe pregnancy nausea.

Abstract

Nausea and vomiting of pregnancy (NVP) is a common condition that affects as many as 70% of pregnant women. Although no consensus definition is available for hyperemesis gravidarum (HG), it is typically viewed as the severe form of NVP and has been reported to occur in 0.3-10.8% of pregnant women. HG can be associated with poor maternal, fetal and child outcomes. The majority of women with NVP can be managed with dietary and lifestyle changes, but more than one-third of patients experience clinically relevant symptoms that may require fluid and vitamin supplementation and/or antiemetic therapy such as, for example, combined doxylamine/pyridoxine, which is not teratogenic and may be effective in treating NVP. Ondansetron is commonly used to treat HG, but studies are urgently needed to determine whether it is safer and more effective than using first-line antiemetics. Thiamine (vitamin B1) should be introduced following protocols to prevent refeeding syndrome and Wernicke encephalopathy. Recent advances in the genetic study of NVP and HG suggest a placental component to the aetiology by implicating common variants in genes encoding placental proteins (namely GDF15 and IGFBP7) and hormone receptors (namely GFRAL and PGR). New studies on aetiology, diagnosis, management and treatment are under way. In the next decade, progress in these areas may improve maternal quality of life and limit the adverse outcomes associated with HG.

Topics

By this author

Related research

Therapeutics › Prescribing Safety › Medication Safety in Pregnancy
Marlena S Fejzo, Jone Trovik, Iris J Grooten, Kannan Sridharan, Tessa J Roseboom, Åse Vikanes, Rebecca C Painter, Patrick M Mullin
M Fejzo, J Trovik, I Grooten, K Sridharan, T Roseboom, Å Vikanes, Becky Painter, R Painter, Pat Mullin, P Mullin
PMID 31515515 31515515 DOI 10.1038/s41572-019-0110-3 10.1038/s41572-019-0110-3 Fejzo et al. 2019, Fejzo 2019